ITA1067
ITA1067
ITA1067
from
$526.00
Price in reward points: 526
- Catalog: ITA1067
- Gene/Protein: MAP3K8
- Product Description: Immunotag™ Phospho-COT (Thr290) Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein Phospho-COT (Thr290) Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC,IF/ICC,ELISA Recommended Dilution WB 1:500-1:2000 IHC 1:50-1:200 IF/ICC 1:100-1:500 Concentration 1 mg/ml Reactive Species Human,Mouse,Rat Host Species Rabbit Immunogen A synthesized peptide derived from human COT around the phosphorylation site of Threonine 290 Specificity Phospho-COT (Thr290) Antibody detects endogenous levels of COT only when phosphorylated at Threonine 290 Purification The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name MAP3K8 Accession No. P41279 Alternate Names AURA2; c COT; Cancer Osaka thyroid oncogene; CCOT; COT; COT proto oncogene serine/threonine protein kinase; EST; ESTF; Ewing sarcoma transformant; FLJ10486; M3K8_HUMAN; MAP3K 8; MAP3K8; MEKK8; Mitogen activated protein kinase kinase kinase 8; Mitogen-activated protein kinase kinase kinase 8; Proto oncogene cCot; Proto-oncogene c-Cot; Serine/threonine protein kinase cot; Serine/threonine-protein kinase cot; TPL 2; TPL-2; TPL2; Tumor progression locus 2; Description Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 60kDa Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | Phospho-COT (Thr290) |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,IF/ICC,ELISA |
| Recommended Dilution | WB 1:500-1:2000 IHC 1:50-1:200 IF/ICC 1:100-1:500 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse,Rat |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human COT around the phosphorylation site of Threonine 290 |
| Specificity | Phospho-COT (Thr290) Antibody detects endogenous levels of COT only when phosphorylated at Threonine 290 |
| Purification | The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | MAP3K8 |
| Accession No. | P41279 |
| Alternate Names | AURA2; c COT; Cancer Osaka thyroid oncogene; CCOT; COT; COT proto oncogene serine/threonine protein kinase; EST; ESTF; Ewing sarcoma transformant; FLJ10486; M3K8_HUMAN; MAP3K 8; MAP3K8; MEKK8; Mitogen activated protein kinase kinase kinase 8; Mitogen-activated protein kinase kinase kinase 8; Proto oncogene cCot; Proto-oncogene c-Cot; Serine/threonine protein kinase cot; Serine/threonine-protein kinase cot; TPL 2; TPL-2; TPL2; Tumor progression locus 2; |
| Description | Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 60kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |